The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals.

The Institute of Cancer Research, London, has been granted the highest national honour in UK further and higher education for its innovative work on breast cancer - a Queen's Anniversary Prize

Professor Kristian Helin, a world-leading cancer researcher and Chief Executive of The Institute of Cancer Research, London, has been elected as a Foreign Member of the Royal Society in recognition of his outstanding contribution to cancer research.